Atlas Trials

Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma

Clinical trial NCT03116529 · TERMINATED

Trial details

NCT number
NCT03116529
Sponsor
University of Maryland, Baltimore
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Soft Tissue Sarcoma
Start date
2017-06-21
Primary completion
2024-06-21
Enrollment
22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.